(Sharecast News) - UK pharma giant GSK and its partner Spero Therapeutics on Wednesday said it had ended a late-stage trial of an experimental drug for complicated urinary tract infections early after it met its main target.
The decision comes after a recommendation from an independent committee that completed a pre-specified interim analysis of data from 1,690 patients enrolled in the trial.

Both firms said the oral drug, known as tebipenem Hbr, was found to be equal to an existing intravenous treatment in hospitalised adult patients.

GSK said it planned to work with US regulatory authorities to include the data as part of a filing in the second half of the year.

Reporting by Frank Prenesti for Sharecast.com

Email this article to a friend

or share it with one of these popular networks:

• DIGG
• FACEBOOK
• STUMBLEUPON
• MIXX
• YAHOO BUZZ
• DELICIOUS
• REDDIT
• NEWSVINE